Is Tarlatamab an oral drug or an intravenous drug?

Tarlatamab (Tarlatamab) is a new type of bispecific T cell-engaging antibody (BiTE) that mainly targets DLL3 (Delta-like ligand 3) and CD3 protein, have the ability to activate T cells and accurately attack cancer cells. Currently, it is mainly used to treat tumor types that highly express DLL3 such as small cell lung cancer (SCLC). Since its molecular structure belongs to the monoclonal antibody class, its administration is not oral but completed through intravenous injection.

Specifically, talatumumab is administered by intravenous infusion and needs to be administered by intravenous drip by a doctor or nurse in a professional medical institution. Oral drugs need to be absorbed through the gastrointestinal tract and tolerate gastric acid. Monoclonal antibody drugs have a large structure and are sensitive to gastric acid and are not suitable for oral administration. Therefore, injection or infusion is usually used for clinical use. Each administration time and dose of talatumumab need to be individually adjusted based on the patient's specific condition, weight, and tolerance.

Because its mechanism of action involves strong activation of T cells, talatumumab may cause immune-related side effects such as cytokine release syndrome (CRS). Therefore, the injection process must be carried out in a medical environment with emergency capabilities so that timely intervention and treatment can be provided when adverse reactions occur. Doctors will closely monitor the patient's physical signs before and during treatment to ensure safe use of the drug.

To sum up, talatumumab is not an oral drug, but a targeted immunotherapy drug administered via intravenous injection. Patients must strictly follow the doctor's recommendations during use and cannot stop the medication or change the administration method on their own to maximize the efficacy and reduce risks. With the development of dosage forms in the future, new administration methods may emerge, but currently intravenous infusion is still the only feasible and safe application route.

Reference materials:https://www.drugs.com/

xa0